Preparation and evaluation of human-murine chimeric antibody against protective antigen of Bacillus anthracis

International Journal of Molecular Sciences

Volumn 15, Issue 10, 2014, Pages 18496-18507

  Hao, Lina ^a   Zheng, Feng ^a   Xiong, Siping ^b   Hu, Dan ^a   Lv, Heng ^a   Tang, Qi ^b   Yang, Jin ^b   Feng, Zhenqing ^b   Wang, Changjun ^a   Zhu, Jin ^a,b  

^a Huadong Medical Institute of Biotechniques   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Anthrax; Chimeric Fab antibody; PA

Indexed keywords

ANTHRAX TOXIN; BACTERIAL ANTIGEN; CHIMERIC ANTIBODY; CHIMERIC FAB MONOCLONAL ANTIBODY; COMPLEMENTARY DNA; IMMUNOGLOBULIN F (AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; UNCLASSIFIED DRUG; BACTERIAL TOXIN; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; NEUTRALIZING ANTIBODY;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTHRAX; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BACILLUS ANTHRACIS; BACTERIOLYSIS; CELL VIABILITY; CONTROLLED STUDY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EXPRESSION VECTOR; FEMALE; HUMAN; HUMAN CELL; HYBRIDOMA CELL LINE; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; MASS SPECTROMETRY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RAT; RECOMBINANT PLASMID; SEQUENCE ANALYSIS; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; FISCHER 344 RAT; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULAR CLONING; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

BACILLUS ANTHRACIS; MURINAE;

AMINO ACID SEQUENCE; ANIMALS; ANTHRAX; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BASE SEQUENCE; CELL LINE; CLONING, MOLECULAR; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOTHERAPY; MICE; MOLECULAR SEQUENCE DATA; RATS; RATS, INBRED F344; RECOMBINANT FUSION PROTEINS;

EID: 84907841514     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151018496     Document Type: Article

References (24)

1. Little, S. F.; Ivins, B. E. Molecular pathogenesis of Bacillus anthracis infection. Microbes Infect. 1999, 2, 131-139.
2. Jernigan, J. A.; Stephens, D. S.; Ashford, D. A.; Omenaca, C.; Topiel, M. S.; Galbraith, M.; Tapper, M.; Fisk, T. L.; Zaki, S.; Popovic, T.; et al. Bioterrorism-Related Inhalational Anthrax: The First 10 Cases Reported in the United States. Emerg. Infect. Dis. 2001, 7, 933-944.
3. Bromberg-White, J.; Lee, C.-S.; Duesbery, N. Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin. Toxins 2010, 2, 1038-1053.
4. Pimental, R.-A. L.; Christensen, K. A.; Krantz, B. A.; Collier, R. J. Anthrax toxin complexes: Heptameric protective antigen can bind lethal factor and edema factor simultaneously. Biochem. Biophys. Res. Commun. 2004, 322, 258-262.
5. Chen, Z.; Moayeri, M.; Purcell, R. Monoclonal antibody therapies against Anthrax. Toxins 2011, 3, 1004-1019.
6. Weiss, S.; Kobiler, D.; Levy, H.; Pass, A.; Ophir, Y.; Rothschild, N.; Tal, A.; Schlomovitz, J.; Altboum, Z. Antibiotics cure anthrax in animal models. Anitimicrob. Agents Chemother. 2011, 55, 1533-1542.
7. Crowe, S. R.; Garmana, l.; Englerc, R. J.; Farrisa, A. D.; Ballardb, J. D.; Harleyb, J. B.; James, J. A. Anthrax vaccination induced anti-lethal factor IgG: Fine specificity and neutralizing capacity. Vaccine 2011, 29, 3670-3678.
8. Mabry, R.; Rani, M.; Geiger, R.; Hubbard, G. B.; Carrion, R., Jr.; Brasky, K.; Patterson, J. L.; Georgiou, G.; Iverson, B. L. Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect. Immun. 2005, 73, 8362-8368.
9. Chow, S.-K.; Casadevall, A. Monoclonal antibodies and toxins-A perspective on function and isotype. Toxins 2012, 4, 430-454.
10. Little, S. F.; Webster, W. M.; Fisher, D. E. Monoclonal antibodies directedagainst protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo. FEMS Immunol. Med. Microbiol. 2011, 62, 11-22.
11. Migone, T.-S.; Subramanian, G. M.; Zhong, J.; Healey, L. M.; Corey, A.; Devalaraja, M.; Lo, L.; Ullrich, S.; Zimmerman, J.; Chen, A.; et al. Raxibacumab for the treatment of inhalational anthrax. N. Engl. J. Med. 2009, 361, 135-144.
12. Froude, J. W., II; Thullier, P.; Pelat, T. Antibodies against anthrax: Mechanisms of action and clinical applications. Toxins 2011, 3, 1433-1452.
13. Abboud, N.; de Jesus, M.; Nakouzi, A.; Cordero, R. J. B.; Pujato, M.; Fiser, A.; Rivera, J.; Casadevall, A. Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies. J. Biol. Chem. 2009, 284, 25077-25086.
14. Li, G.; Qu, Y.; Cai, C.; Kong, Y.; Liu, S.; Zhang, J.; Zhao, J.; Fu, L.; Xu, J.; Chen, W. The inhibition of the interaction between the anthrax toxin and its cellular receptor by an anti-receptor monoclonal antibody. Biochem. Biophys. Res. Commun. 2009, 385, 591-595.
15. Vitale, L.; Blanset, D.; Lowy, I.; O'Neill, T.; Goldstein, J.; Little, S. F.; Andrews, G. P.; Dorough, G.; Taylor, R. K.; Keler, T. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect. Immun. 2006, 74, 5840-5847.
16. Little, S. F.; Leppla, S. H.; Cora, E. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 1988, 56, 1807-1813.
17. Brossier, F.; Levy, M.; Landier, A.; Lafaye, P.; Mock, M. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect. Immun. 2004, 72, 6313-6317.
18. Chen, Z.; Moayeri, M.; Zhou, Y.-H.; Leppla, S.; Emerson, S.; Sebrell, A.; Yu, F.; Svitel, J.; Schuck, P.; St Claire, M.; et al. Efficient Neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J. Infect. Dis. 2006, 193, 625-633.
19. Staats, H. F.; Alam, S. M.; Scearce, R. M.; Kirwan, S. M.; Zhang, J. X.; Gwinn, W. M.; Hayneset, B. F. In vitro and In vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect. Immun. 2007, 75, 5443-5452.
20. Stahl, S. J.; Watts, N. R.; Rader, C.; Dimattia, M. A.; Mage, R. G.; Palmer, I.; Kaufman, J. D.; Grimes, J. M.; Stuart, D. I.; Steven, A. C.; et al. Generation and characterization of a chimeric rabbit/human Fab for co-crystallization of HIV-1 Rev. J. Mol. Biol. 2010, 397, 697-708.
21. Coleman, L.; Mahler, S. M. Purification of Fab fragments from a monoclonal antibody papain digest by gradifiow electrophoresis. Protein Expr. Purif. 2003, 32, 246-251.
22. Laffly, E.; Pelat, T.; Cédrone, F.; Blesa, S.; Bedouelle, H.; Thullier, P. Improvement of an antibody neutralizing the anthrax toxin by simultaneous mutagenesis of its six hypervariable loops. J. Mol. Biol. 2008, 378, 1094-1103.
23. Li, C.; Zhang, F.; Lin, H.; Wang, Z.; Liu. X.; Feng, Z.; Zhu, J.; Guan, X. Generation and characterization of the human neutralizing antibody fragment Fab091 against rabies virus. Acta Pharmacol. Sin. 2011, 32, 329-337.
24. VBASE2-The Integrative Germ, Line V Gene Database. Available online: http://www. vbase2. org/(accessed on 30 August 2013).